ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies (2021)
Attributed to:
Phase 1 COVID-19 Immunity - National Core Study
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2021.04.06.438630
Publication URI: http://dx.doi.org/10.1101/2021.04.06.438630
Type: Preprint